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from genetically intractable bacteria results in
scleric acid discovery†
Fabrizio Alberti, *ab Daniel J. Leng, b Ina Wilkening, b Lijiang Song, b
Manuela Tosin b and Christophe Corre *ab
In this study, we report the rapid characterisation of a novel microbial natural product resulting from the
rational derepression of a silent gene cluster. A conserved set of ﬁve regulatory genes was used as
a query to search genomic databases and identify atypical biosynthetic gene clusters (BGCs). A 20-kb
BGC from the genetically intractable Streptomyces sclerotialus bacterial strain was captured using yeast-
based homologous recombination and introduced into validated heterologous hosts. CRISPR/Cas9-
mediated genome editing was then employed to rationally inactivate the key transcriptional repressor
and trigger production of an unprecedented class of hybrid natural products exempliﬁed by
(2-(benzoyloxy)acetyl)-L-proline, named scleric acid. Subsequent rounds of CRISPR/Cas9-mediated gene
deletions aﬀorded a selection of biosynthetic gene mutant strains which led to a plausible biosynthetic
pathway for scleric acid assembly. Synthetic standards of scleric acid and a key biosynthetic intermediate
were also prepared to conﬁrm the chemical structures we proposed. The assembly of scleric acid
involves two unique condensation reactions catalysed by a single NRPS module and an ATP-grasp
enzyme that link a proline and a benzoyl residue to each end of a rare hydroxyethyl-ACP intermediate,
respectively. Scleric acid was shown to exhibit moderate inhibition activity against Mycobacterium
tuberculosis, as well as inhibition of the cancer-associated metabolic enzyme nicotinamide
N-methyltransferase (NNMT).Introduction
Actinomycete bacteria have been the foremost producers of
antibiotics since the mid-1940s. In the last decade, high-
throughput DNA sequencing technologies and novel bio-
informatics tools have highlighted an immense number of
uncharacterised biosynthetic gene clusters (BGCs) predicted to
direct the assembly of bioactive natural products.1 The presence
of BGCs has not only been revealed in actinomycete genomes
but also in those of human commensal and pathogenic bacteria
(i.e. Staphylococcus lugdunensis, Burkholderia cepacia complex),
as well as in the genomes of unculturable bacteria and in
metagenomic libraries.2–7
Despite the conspicuous number of specialised metabolites
isolated from actinomycetes, only a small fraction of the natural
products ‘encrypted’ at the DNA level has been exploited to date.
Experimental characterisation of the biosynthetic product ofe and School of Life Sciences, University of
il: F.Alberti@warwick.ac.uk; C.Corre@
rwick, Coventry, CV4 7AL, UK
ESI) available: Supplementary methods
e DOI: 10.1039/c8sc03814g
Chemistry 2018a BGC is oen laborious and time-consuming particularly due
to the uniqueness of every microorganism. Protocols for intro-
ducing DNA into bacterial cells are species-dependent and oen
ineﬀective. Their optimisation can take years but many cultur-
able micro-organisms remain genetically intractable. This
prevents the exploitation of BGCs using many of the previously
reported strategies.1 In addition, the biosynthesis of specialised
metabolites is oen tightly controlled at the transcriptional
level. Cluster-associated transcriptional regulators that belong
to the TetR-family of transcriptional repressors are particularly
numerous.8 Deletions of cluster-specic TetR-like transcrip-
tional repressors have been shown to trigger overproduction of
the corresponding specialised metabolites, as previously re-
ported for the antibiotics methylenomycin and coelimycin in
Streptomyces coelicolor A3(2) and for the urea-containing
gaburedins in Streptomyces venezuelae.9–12
Genetic manipulation of Streptomyces genomes has classi-
cally been accomplished using established but oen laborious
protocols optimised for specic bacterial strains.13 In recent
years however, targeted genome editing has been revolutionised
by the advent of clustered regularly interspaced short palin-
dromic repeats (CRISPR)/CRISPR-associated (Cas) systems,
which allow generation of clean genomic deletions/insertions.14
Toolkits for editing streptomycete genomes have beenChem. Sci.
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View Article Onlinedeveloped,15–17 enabling researchers to overcome the issues
associated with classical methods of gene disruption, in
particular when multiple mutation events are desirable.18 The
number of available selectable markers and issues with poten-
tial restoration of the wild-type conguration due to occurrence
of single-crossover events were notable limitations.
Here, we report a genome mining strategy based on the
identication of a conserved regulatory cassette for selecting
and characterising BGCs. A specic BGC was rst captured and
transferred into a validated Streptomyces heterologous host
where CRISPR/Cas9-mediated genome editing was employed to
rationally derepress the expression of silent biosynthetic genes
(Fig. 1). This approach was applied for the identication,Fig. 1 Overview of the approach used in this study to characterise scler
Chem. Sci.isolation and structural elucidation of a novel structural class of
natural products from a silent and cryptic gene cluster found in
the soil-dwelling species Streptomyces sclerotialus NRRL ISP-
5269, a species of lamentous bacteria rst isolated in Poona
(India).19Results and discussion
Identication of the scl gene cluster in S. sclerotialus NRRL
ISP-5269
The prioritisation of the gene cluster under study was guided
by the presence of a specic set of ve regulatory genes that we
had previously characterised in S. coelicolor A3(2),9 andic acid, a novel natural product from a cryptic and silent gene cluster.
This journal is © The Royal Society of Chemistry 2018
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View Article Onlinesubsequently exploited to trigger the expression of a silent and
cryptic biosynthetic gene cluster in Streptomyces venezuelae.12 In
S. coelicolor A3(2), these ve genes are responsible for regulation
of methylenomycin biosynthesis:mmyR andmmfR both code for
TetR-like transcriptional repressors; mmfLHP are responsible
for the biosynthesis of signalling molecules, known as methyl-
enomycin furans (MMFs) that trigger production of the meth-
ylenomycin antibiotics.9 A mathematical model that explains in
detail the methylenomycin regulatory system involving these
ve genes has been developed and matched with experimental
data.20 In previous studies we have exploited this regulatory
cassette and shown that inactivation of the mmyR-like tran-
scriptional repressors is an eﬀective approach for derepressing
silent gene clusters in actinomycetes.10,12
In order to nd gene clusters that contained regulatory
cassettes homologous to the one found in the methylenomycin
cluster and to assess how widespread these are, we performed
searches with Multigene BLAST21 using as a query the DNA
sequences of mmyR, mmfR and mmfLHP, as well as with Clus-
terTools,22 using as a query the protein sequences of MmyR,
MmfR and MmfLHP. Fourteen actinomycete genomes were
found that contained orthologues of all ve genes coding for
MmyR, MmfR and MmfLHP within a 50-kb region (ESI Table
S4†). Remarkably, a total of 98 actinomycete genomes were
found that contained orthologues of at least mmyR, mmfR and
mmfL within a 50-kb region. We have previously shown that the
butenolide synthase MmfL alone is suﬃcient to give production
of functional MMF signalling molecules in S. coelicolor A3(2).9Fig. 2 Genetic organisation of the scl gene cluster from S. sclerotialus N
of mutants generated. (a) Gene cluster (19 782 bp) sequenced from S. scl
CRISPR/Cas9-mediated targeted gene deletion within the heterologou
a truncated gene, represented here as a rectangular shape for the deriv
double mutants; deletion of genes sclN, sclQ1-4 and sclA were generate
dotted lines.
This journal is © The Royal Society of Chemistry 2018Additionally, a functional regulatory system that controls
biosynthesis of coelimycin antibiotics in S. coelicolor A3(2) has
been characterised that includes the butenolide synthase ScbA
and the two TetR-like transcriptional regulators ScbR and
ScbR2,11 which are orthologues of MmfL, MmfR and MmyR
respectively. Hence the regulatory systems that include ortho-
logues of mmyR, mmfR and mmfL are also putatively functional,
and the biosynthetic products they regulate expression of could
also be studied via manipulation of these regulatory cassettes.
Among the hits generated, the gene cluster from S. sclerotialus
NRRL ISP-5269, named hereaer scl cluster, was chosen for
further study; the nucleotide sequence containing the scl
cluster was available from the GenBank accession number
JOBC01000043.1. In addition to homologues of the ve genes
used as query, the genetic organisation of the scl gene cluster
included two adjacent and divergent operons of biosynthetic
genes (Fig. 2a). A combination of AntiSMASH23 and manual
BLASTp24 analyses indicated the putative borders of the scl
cluster (Fig. 2a and Table 1). The predictive power of these
modern bioinformatics tools oen permits to deduce the
chemical structure(s) of cryptic gene cluster products, partic-
ularly whenmodular systems such as type I modular polyketide
synthases (PKS) or non-ribosomal peptide synthetases (NRPS)
direct the biosynthesis.25 However, the originality of the scl
cluster prevented such predictions and we worked on the
assumption that a lack of bioinformatics prediction was more
likely to result in a more structurally diverse and therefore
truly novel natural product. The cluster spanned a region ofRRL ISP-5269 characterised in this study and schematic representation
erotialus NRRL ISP-5269. (b) Conﬁguration of the scl gene cluster after
s host S. albus. The 20-bp out of frame deletion of sclM4 generated
ed gene sequence. (c) Conﬁguration of the scl cluster within S. albus
d starting from strain S. albus/scl DsclM4, and are represented here as
Chem. Sci.
Table 1 Proposed function of the biosynthetic, regulatory and resistance genes from the scl gene cluster
Protein (number of aa) GenBank
Homologue (% identity/%
similarity) organism GenBank Putative function Proposed role
SclP (213) WP_037773640.1 4-Phosphopantetheinyl transferase
(54/61) Streptomyces pristinaespiralis
WP_078951206.1
PPTase
Biosynthesis of the glycolic acid unit
SclQ4 (386) WP_030624999.1 QncL (37/49) Streptomyces
melanovinaceus AFJ11255.1 (ref. 34)
Lipoyl attachment domain,
acyltransferase catalytic domain
SclQ3 (338) WP_030625001.1 QncL (51/68) S. melanovinaceus
AFJ11255.1 (ref. 34)
Pyrimidine binding domain,
transketolase C-terminal domain
SclQ2 (305) WP_078889003.1 QncN (61/73) S. melanovinaceus
AFJ11257.1 (ref. 34)
ThDP binding domain
SclQ1 (76) WP_030625009.1 QncM (32/68) S. melanovinaceus
AFJ11256.1 (ref. 34)
Acyl carrier protein (ACP)
SclM1 (200) WP_078889004.1 MmfR (56/73) Streptomyces
coelicolor A3(2) WP_011039544.1
(ref. 9 and 10)
TetR-family transcriptional
repressor
Regulation of the expression of
scleric acid biosynthetic genes
SclM2 (336) WP_078889005.1 MmfL (35/47) S. coelicolor A3(2)
WP_011039545.1 (ref. 9 and 10)
Signaling molecule biosynthesis
(butenolide synthase)
SclL (106) WP_051872433.1 LysR family transcriptional
regulator (61/72) S. venezuelae
WP_015035381.1
LysR transcriptional regulator
SclM3 (228) WP_078889008.1 MmfP (46/56) S. coelicolor A3(2)
WP_011039547.1 (ref. 9 and 10)
Signaling molecule biosynthesis
(hydrolase)
SclM4 (196) WP_051872434.1 MmyR (41/56) S. coelicolor A3(2)
WP_011039548.1 (ref. 9 and 10)
TetR-family transcriptional
repressor
SclM5 (378) WP_051872435.1 MmfH (49/59) S. coelicolor A3(2)
WP_011039546.1 (ref. 9 and 10)
Signaling molecule biosynthesis
(oxidoreductase)
SclN (1083) WP_078889006.1 PuwA (32/48) Cylindrospermum
alatosporum CCALA 988 AIW82277.1
(ref. 32)
NRPS [C-A-PCP] Activation of L-proline and
condensation with glycolic acid
SclT (243) WP_030625041.1 Thioesterase (45/56) Streptomyces
sviceus WP_007379259.1
Thioesterase (TE) Hydrolytic release of scleric acid
from a carrier protein
SclA (656) WP_051872438.1 PauY18 (56/67) Streptomyces sp.
YN86 AIE54238.1 (ref. 33)
Anthranilate synthase
Biosynthesis of the benzoic acid
unit
SclD (405) WP_030625030.1 PauY21 (55/65) Streptomyces sp.
YN86 AIE54241.1 (ref. 33)
DAHP synthase
SclI (220) WP_030625033.1 PauY19 (57/71) Streptomyces sp.
YN86 AIE54239.1 (ref. 33)
Isochorismatase
SclG (439) WP_030625035.1 ATP-grasp domain-containing
protein (49/62) Streptomyces sp.
NRRL B-5680 WP_051746523.1
ATP-grasp family enzyme Condensation reaction of the
proline unit with benzoic acid
SclE (435) Major Facilitator Superfamily
transporter (53/65) Amycolatopsis
vancoresmycina WP_003090471.1
MFS transporter Export of scleric acid outside the
cell
Chemical Science Edge Article
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View Article Online19 782 bp, and comprised 18 putative genes: 11 biosynthetic
genes, 6 genes for regulation and 1 gene coding for
a membrane transporter (Fig. 2a and Table 1).Capture of the scl gene cluster and introduction into
heterologous hosts
In order to characterise the product of the scl cluster, we rst
set out to examine the genetic tractability of S. sclerotialus
NRRL ISP-5269. To do so, we attempted introduction of
plasmid pCRISPomyces-2 (ref. 15) for CRISPR/Cas9-basedChem. Sci.genome engineering via intergeneric-conjugation of mycelia
with E. coli ET12567/pUZ8002 or protoplast transformation
but these processes were found ineﬀective.13 The preparation
of S. sclerotialus NRRL ISP-5269 spores was also attempted but
despite screening various culture media in the aim to induce
sporulation, this strain showed little aerial growth. We there-
fore set out to capture and heterologously express the scl gene
cluster, with the aim of characterising its biosynthetic prod-
uct(s) in a well-characterised and genetically amenable host.
A 33-kb region of genomic DNA that included the 19.8-kb
scl BGC was captured from the puried genomic DNA ofThis journal is © The Royal Society of Chemistry 2018
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View Article OnlineS. sclerotialus ISP-5269 via transformation-associated recom-
bination (TAR) cloning (ESI Fig. S1†).26 A pCAP03-derived
plasmid was rst assembled to specically recombine in
yeast with both extremities of the 33-kb target DNA fragment.27
The pCAP03-scl construct was introduced and stably integrated
into the genome of Streptomyces albus J1074 and S. coelicolor
M1152 via intergeneric tri-parental conjugation with E. coli
ET12567/pCAP03-scl and E. coli ET12567/pUB307. These two
strains were chosen as they are well characterised chassis for
heterologous expression of actinomycete gene clusters.28,29 In
parallel, the negative control strains S. albus/pCAP03 and S.
coelicolor M1152/pCAP03 were generated using the “empty”
pCAP03 plasmid. The four Streptomyces strains were grown on
supplemented minimal agar medium for 5 days, and the
acidied agar medium was extracted with ethyl acetate. Their
metabolic proles were analysed by ultra-high-pressure liquid
chromatography-high resolution mass spectrometry (UHPLC-
HRMS). Comparison of the MS chromatograms failed to
reveal any new compounds in the heterologous hosts where the
scl BGC had been integrated.Fig. 3 Identiﬁcation and characterisation of scleric acid. (a) UHPLC-HRM
S. albus/scl (black), S. albus/scl DsclM4 (orange), S. albus/scl DsclM4 Dsc
DsclA (red). Extracted ion chromatograms in positive mode for m/z ¼
(scleric acid) at retention time 16.4 minutes in S. albus/scl DsclM4 (orang
spectrum in positive mode of scleric acid. (d) Selected correlations obser
acid. (e) Chemical structure of scleric acid that can adopt two main rota
This journal is © The Royal Society of Chemistry 2018Derepression of the scl gene cluster and characterisation of
scleric acid
The lack of accumulation of novel metabolites in the scl-con-
taining strains was likely to be due to the transcriptional
repression activity of the TetR-like regulators encoded in the scl
cluster. We had previously shown that genetic inactivation of
mmyR-like genes in S. coelicolor A3(2) and in S. venezuelae would
specically derepress the expression of adjacent BGCs.10,12 We
therefore decided to genetically inactivate the mmyR homolo-
gous gene, sclM4 using the CRISPR/Cas9-based plasmid
pCRISPomyces-2 (pCm2).15 For this purpose, we assembled the
plasmid pCm2-sclM4 and attempted intergeneric-conjugation
of S. albus/scl and S. coelicolor M1152/scl with E. coli ET12567/
pUZ8002/pCm2-sclM4. Ex-conjugants for strain S. albus/scl
DsclM4 (see Fig. 2b for a representation of the genotype) were
readily obtained, however no ex-conjugants could be obtained
when attempting insertion of plasmid pCm2-sclM4 into
S. coelicolor M1152/scl. The desired 20-bp out-of-frame deletion
of sclM4 was conrmed by sequencing of a PCR product usingS detection of metabolites produced in S. albus/pCAP03 (grey trace),
lQ1-4 (blue), S. albus/scl DsclM4 DsclN (green) and S. albus/scl DsclM4
278.1020 are shown, highlighting accumulation of a new metabolite
e trace). (b) UV chromatogram of scleric acid. (c) High-resolution mass
ved in the COSY (bold lines) and HMBC (arrows) NMR spectra of scleric
mer conformations.
Chem. Sci.
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View Article OnlineS. albus/scl DsclM4 genome as a template (ESI Fig. S2†).
Metabolites produced by this strain were compared by UHPLC-
HRMS to those of S. albus/scl and S. albus/pCAP03 grown under
the same conditions as those described earlier. S. albus/scl
DsclM4 showed accumulation of a major metabolite (Fig. 3a–c)
with a retention time of 16.4 minutes on C18 reverse phase
HPLC column and an m/z value of 278.1020 [M(C14H15NO5) +
H]+ (calculated m/z of 278.1023). This compound was puried
using a combination of ash chromatography on C18-silica
column and HPLC. Its structure was then elucidated by
a combination of 1D- and 2D-NMR spectroscopy experiments
(ESI Fig. S5–S9†). The novel compound was characterised as
being (2-(benzoyloxy)acetyl)-L-proline and named scleric acid
(Fig. 3d).
In order to establish the stereochemistry of the proline
residue, scleric acid was hydrolysed and derivatised with Mar-
fey's reagent.30 L- and D-proline were also derivatised using the
same procedure and used as standards for HPLC comparison.
Approximately 95% of the proline residue of scleric acidFig. 4 Proposed biosynthetic pathway to scleric acid.
Chem. Sci.puried from S. albus/scl DsclM4 was found to correspond to L-
proline (ESI Fig. S10†). To conrm the proposed structure of
scleric acid, an authentic standard was synthesised (see ESI
Fig. S20† for a schematic representation of the synthetic route).
A structural analogue, 2-((benzoyl-L-prolyl)oxy)acetic acid,
possibly consistent with the initial NMR data obtained, was also
synthesised (see ESI Fig. S21† for a schematic representation of
the synthetic route and ESI Fig. S11–S15† for NMR spectra). LC-
MS analyses and NMR data of both of these compounds
unequivocally conrmed the proposed structure for scleric acid
(Fig. 3); the analogue revealed diﬀerent NMR spectra and its
physico-chemical properties resulted in a diﬀerent retention
time on LC-MS. Moreover, two sets of NMR signals were
observed for the puried natural product as well as for the
synthetic standard and revealed that scleric acid existed as two
diﬀerent rotamers, trans- and cis-scleric acid (Fig. 3e and ESI
Fig. S5†). This is consistent with literature data for synthetic
N-benzoyl-L-proline methyl ester where a 4 : 1 mixture of the two
rotamers was observed.31This journal is © The Royal Society of Chemistry 2018
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View Article OnlineDening key biosynthetic genes in the scl cluster
BLASTp analyses24 combined with the elucidated structure for
scleric acid allowed us to propose plausible functional assign-
ments for all the biosynthetic enzymes coded in the scl BGC
(Table 1 and Fig. 4).32–34 Three main building blocks were
identied as being part of scleric acid: a glycolic acid unit
(highlighted in red in Fig. 4), a benzoic acid unit (in magenta in
Fig. 4) and an L-proline residue (in blue in Fig. 4). The origin of
these three building blocks and the overall biosynthesis of
scleric acid are discussed in detail here.
The four proteins encoded by genes sclQ1-4 showed high
homology to a set of three enzymes – QncN, QncL and QncM –
from Streptomyces melanovinaceus. This set of enzymes has been
shown to direct the biosynthesis and attachment of a C2-gly-
colicacyl unit to a non-ribosomal peptide.34 More specically,
SclQ2 was homologous to QncN, a thiamin diphosphate (ThDP)
binding domain. SclQ3 was homologous to the rst two N-
terminal domains of QncL, a pyruvate dehydrogenase/
transketolase pyrimidine binding domain and a transketolase
C-terminal domain while SclQ4 was homologous to the last two
domains of QncL, a lipoyl attachment domain and an acyl-
transferase catalytic domain. Lastly, SclQ1 was homologous to
the acyl carrier protein (ACP) QncM. Based on the homology of
SclQ1-4 with QncN, QncL and QncM, we propose that SclQ1-4
are overall responsible for converting of a ketose phosphate
from the primary metabolism (such as xylulose-5-phosphate)
into the activated glycolic acid unit found in scleric acid.
The three-gene cassette made of sclA, sclD and sclI showed
high homology to genes involved in biosynthesis of a benzoic
acid unit in Streptomyces sp. YN86.33 Specically, SclA showed
high similarity to the anthranilate synthase enzyme PauY18,
SclD to the DAHP synthase PauY21 and SclI to the iso-
chorismatase PauY19. Overall these three enzymes were
hypothesised to be responsible for biosynthesis of the benzoyl
group found in scleric acid via chorismate as an intermediate.
SclN was predicted to be a NRPS enzyme consisting of
a single minimal elongation module: a putative, atypical
condensation domain (C), an adenylation domain (A) and
a peptidyl carrier protein (PCP) domain.35 The SclN A-domain
was predicted to specically activate L-proline, which was in
accordance with the presence of a L-proline residue in scleric
acid.25 The SclN C-domain was proposed to catalyse the amide
bond formation between L-proline and glycolic acid.
Other genes putatively involved in biosynthesis and export of
scleric acid and present in the scl cluster are: sclT, sclG and sclE.
The thioesterase SclT is predicted to release the L-proline–oxy-
acetic acid intermediate from the PCP-domain of SclN. We
propose that the ATP-grasp family enzyme SclG would bind and
activate the benzoic acid unit produced by SclADI. That same
enzyme would also promote condensation of the benzoyl unit
with L-proline–oxyacetic acid, giving scleric acid. This would be
exported out of the cell by the putative MFS transporter SclE.
In order to conrm the proposed involvement of the
enzymes SclN, SclA and SclQ1-4 in the biosynthesis of the
building blocks that make up scleric acid, we constructed gene
deletion mutants in strains where the transcriptional repressorThis journal is © The Royal Society of Chemistry 2018sclM4 has also been inactivated (S. albus/scl DsclM4 back-
ground). Plasmids pCm2-sclN, pCm2-sclA and pCm2-sclQ1-4
were assembled and used to generate double mutant strains
S. albus/scl DsclM4 DsclN, S. albus/scl DsclM4 DsclA and
S. albus/scl DsclM4 DsclQ1-4. Deletions were conrmed by PCR
screening (ESI Fig. S3†). UHPLC-HRMS analysis revealed that
production of scleric acid was abolished in S. albus/scl DsclM4
DsclN and S. albus/scl DsclM4 DsclA (Fig. 3a), conrming the
essential role of SclN and SclA. Residual scleric acid production
was detected from S. albus/scl DsclM4 DsclQ1-4; this could be
explained by the fact that glycolic acid is known to be produced
by Streptomyces species in particular for the biosynthesis of
N-glycolylmuramic acid.36 Addition of 5 mM glycolic acid to the
culture medium of S. albus/scl DsclM4 DsclQ1-4 also resulted in
scleric acid being produced in similar level to that observed
with S. albus/scl DsclM4 (ESI Fig. S16†).
The identication of key precursors in scleric acid biosyn-
thesis was also exploited to further increase the titres of scleric
acid produced by S. albus/scl DsclM4. Enriching the culture
medium with 5 mM L-proline, 5 mM benzoic acid or 5 mM
glycolic acid signicantly increased levels of scleric acid
observed upon UHPLC-HRMS analysis of the ethyl acetate
extracts compared to those observed with S. albus/scl DsclM4
grown on the standard supplemented minimal medium
(ESI Fig. S17†). The strategy of manipulating the pathway-
specic transcriptional regulatory system also makes scleric
acid production not reliant on a complex culture medium.
Importantly the utilisation of supplemented minimal media
does signicantly facilitate the isolation of the natural product
of interest.Evidence for proposed biosynthetic intermediates
Based on the predicted function of the scl biosynthetic genes,
we therefore proposed a putative biosynthetic route to scleric
acid as shown in Fig. 4. A glycolic acid unit is believed to be
produced by SclQ2-4 and loaded onto the SclQ1 ACP. SclP would
convert apo-SclQ1 into holo-SclQ1 by phosphopantetheinyla-
tion. Meanwhile the adenylation domain of the NRPS SclN
would activate L-proline, which could then be condensed to the
glycolic acid unit through the activity of the C-domain of SclN.
The L-proline–oxyacetic acid intermediate would then be
released from the PCP-domain of SclN by the activity of the
thioesterase SclT. The three enzymes SclADI would direct the
biosynthesis of the benzoic acid moiety, which would be acti-
vated by the ATP-grasp family enzyme SclG. That same enzyme
would also catalyse the condensation of the benzoyl unit with
L-proline–oxyacetic acid, giving scleric acid. Lastly, scleric acid
would be exported out of the cell by the putative MFS trans-
porter SclE.
In support to this proposed pathway, we investigated by
UHPLC-HRMS accumulation of the L-proline–oxyacetic acid
intermediate from the ethyl acetate extracts of the scleric acid
producing strain, as well as of the double mutant strains. A
compound with a retention time of 3.0 minutes on C18 reverse
phase HPLC column and an m/z value of 174.0763
[M(C7H12NO4) + H]
+ (calculatedm/z of 174.0761) was detected inChem. Sci.
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View Article Onlinethe scleric acid producing strain S. albus/sclDsclM4, as well as in
the double mutants S. albus/scl DsclM4 DsclQ1-4 and S. albus/scl
DsclM4 DsclA (ESI Fig. S18†). Consistent with the predicted
function of the L-proline-activating NRPS SclN, strain S. albus/scl
DsclM4 DsclN did not show any accumulation of L-proline–oxy-
acetic acid. In order to further conrm the identity of this
intermediate, which was detected from the crude extracts in
amounts not suﬃcient for HPLC purication and subsequent
NMR characterisation, a synthetic standard was prepared (see
ESI Fig. S22† for a schematic representation of the synthetic
route) and run alongside the crude extracts on UHPLC-HRMS.
This showed the same retention time and mass spectrum as
the natural product L-proline–oxyacetic acid intermediate (ESI
Fig. S18†). Moreover, we grew S. albus/scl DsclM4 DsclN, unable
to produce scleric acid, in the presence of 5 mM L-proline–
oxyacetic acid. Feeding the intermediate to the mutant strain
restored production of scleric acid, as visible from UHPLC-
HRMS analysis of its acidied ethyl acetate extracts (ESI
Fig. S19†). This provides additional evidence that L-proline–
oxyacetic acid is a true intermediate in scleric acid biosynthesis.
It also suggests that the L-proline–oxyacetic acid is released
from the C-domain of SclN prior to SclG catalysing its conden-
sation with the benzoyl group, in accordance with the order of
reactions proposed in Fig. 4.Biological activity of scleric acid
The antimicrobial activity of scleric acid was assessed. Inhibi-
tory activity against representatives of the ESKAPE panel of
pathogens: Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter cloacae was rst screened but all
strains appeared to be resistant to scleric acid, giving no
observable MIC (ESI Table S6†).
Scleric acid was then tested for a broader range of pharma-
ceutically relevant bioactivities through the Eli Lilly Open
Innovation Drug Discovery (OIDD) Program. In a single point
(20 mM) primary assay, scleric acid showed moderate antibac-
terial activity against Mycobacterium tuberculosis (H37Rv),
exhibiting a 32% inhibition on the growth of this strain.
Scleric acid showed inhibitory activity on the cancer-
associated metabolic enzyme nicotinamide N-methyltransfer-
ase (NNMT), the overexpression of which is known to contribute
to tumorigenesis.37 NNMT catalyses the transfer of a methyl
group from S-adenosyl-L-methionine (SAM) to nicotinamide,
generating S-adenosyl-L-homocysteine (SAH) and 1-methyl-
nicotinamide (MNAN).37 Scleric acid showed, on a concentra-
tion response curve assay, IC50 of 178.0 mM (NNMT MNAN) and
186.6 mM (NNMT SAH) (ESI Fig. S4†).Conclusions
Specialised metabolites from actinomycete bacteria are one of
the most valuable sources of novel antibiotics, as well as of
other useful bioactive compounds employed in various elds,
from human medicine to crop protection. High-throughput
sequencing of bacterial genomes/metagenomes has becomeChem. Sci.quick and inexpensive, and is unearthing a myriad of putative
gene clusters that are awaiting to be characterised and exploi-
ted. In this study, we have demonstrated that a cryptic gene
clusters from a genetically intractable actinomycete could be
successfully exploited for characterising the biosynthetic
pathway it encodes as well as the resulting natural product. In
principle, the same approach could be used with metagenomic
DNA. Our strategy rst relied on the bioinformatics identica-
tion and selection of cryptic gene clusters containing a charac-
terised regulatory system (Fig. 1). A DNA fragment containing
the entire gene cluster was then captured via TAR cloning and
introduced in the genome of a validated heterologous host.
Expression of the biosynthetic genes was then triggered through
CRISPR/Cas9-mediated editing of the key mmyR-like transcrip-
tional repressor. Analytical chemistry procedures were then
undertaken to identify, isolate and characterise the new natural
product, overproduced in the heterologous host. Finally,
subsequent rounds of CRISPR/Cas9-mediated gene deletions
targeted putative biosynthetic genes and aﬀorded mutant
strains. In turn, a biosynthetic route to the novel natural product
could be proposed. This approach was validated by the discovery
of (2-(benzoyloxy)acetyl)-L-proline, named scleric acid, from the
genome of the soil-dwelling lamentous bacterium Streptomyces
sclerotialus NRRL ISP-5269. Based on the predicted function of
the Scl enzymes and the detection of a key intermediate from
culture extracts of selected strains a plausible biosynthetic route
to scleric acid was proposed (Fig. 4). In addition to the novel
biochemistry this biosynthetic pathway oﬀers, scleric acid has
been shown to exhibit moderate antibacterial activity against
M. tuberculosis, as well inhibition on the cancer-associated
enzyme nicotinamide N-methyltransferase (NNMT). We are
currently investigating scleric acid bioactivity further through
the Eli Lilly Open Innovation Drug Discovery (OIDD) Program.
The widespread presence of orthologues of the methyl-
enomycin regulatory genes among actinomycete genomes (ESI
Table S4†) revealed that the approach described herein might
be very promising for the discovery and characterisation of
novel natural products, and therefore, of novel biocatalysts.
Comparative genomics analyses also indicated that there is no
apparent correlation between the presence of the regulatory
cassette we targeted and the type of natural products that they
regulate production of – both in relation to biosynthesis and
bioactivity – methylenomycin,9 gaburedins12 and scleric acid
being examples of natural products characterised so far.
In conclusion, beyond the discovery of this specialised
metabolite, we strongly believe that targeting conserved
pathway-specic regulatory elements, as opposed to mining
BGCs encoding dened enzymatic machineries (i.e. PKS, NRPS),
will lead to the identication and characterisation of microbial
natural products assembled by truly novel types of biocatalysts.
Materials and methods
Bioinformatics analysis
The whole genome sequence of Streptomyces sclerotialus NRRL
ISP-5269 was downloaded from the Genomes Online Database
of the JGI Portal (U.S. Department of Energy, https://This journal is © The Royal Society of Chemistry 2018
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View Article Onlinegold.jgi.doe.gov/, GOLD Project ID Gp0187859). Contig43 of the
genome contained the scl gene cluster object of this study. A
combination of AntiSMASH23 and manual BLASTp24 analyses
allowed to dene the putative borders of the scl cluster and
predict the function of the encoded enzymes. The website for
PKS/NRPS analysis from the University of Maryland was used
for domain prediction of SclN.25 SerialCloner 2.6.1 (SerialBasics)
was used for DNA sequence analysis and plasmid design. Mul-
tigene BLAST21 was used to search for gene clusters that
included homologues of the methylenomycin regulatory genes
from S. coelicolor A3(2) and allowed to pinpoint the scl BGC from
S. sclerotialus NRRL ISP-5269. ClusterTools was used to search
orthologues of the proteins involved in regulation of methyl-
enomycin production in other actinomycetes (ESI Table S4†), as
well as orthologues of the scl cluster proteins in other actino-
mycetes (ESI Table S5†).22
Reagents
All chemicals were purchased from Sigma-Aldrich, unless
otherwise stated. Phusion DNA polymerase, as well as all
restriction endonucleases, T4 DNA ligase, shrimp alkaline
phosphatase (rSAP) and Gibson Assembly cloning kit, were
purchased from New England Biolabs. Zymolyase 20T was
purchased from MP Biomedicals, 5-uoroorotic acid (5-FOA)
was purchased from Thermo Fisher Scientic. Primers for PCR
amplication were purchased from Sigma-Aldrich (see ESI
Table S3† for a list of oligonucleotides used in this study).
Culturing and engineering of microorganisms
Streptomyces sclerotialus NRRL ISP-5269 was obtained from JCM
(Japan Collection of Microorganisms, culture collection number
4828T) (see ESI Table S1† for a list of strains used in this study).
Streptomyces albus J1074 and Streptomyces coelicolorM1152 were
used for heterologous expression. All Streptomyces strains were
grown on soya our mannitol (SFM) agar medium (20 g L1 soya
our, 20 g L1 mannitol, 20 g L1 agar), with appropriate anti-
biotic selection upon insertion of plasmid DNA (50 mg mL1
apramycin when transformed with pCRISPomyces-2-derived
plasmids; 25 mg mL1 kanamycin when transformed with
pCAP03-derived plasmids; 25 mg mL1 nalidixic acid on the rst
round of subculture aer intergeneric conjugation). E. coli
ET12567 and ET12567/pUB307 were used for the purpose of
intergeneric tri-parental conjugation. One Shot TOP10 chemi-
cally competent E. coli cells (Thermo Fisher Scientic) were used
for cloning and storage of plasmid DNA. All E. coli strains were
grown on lysogeny broth (LB) medium (10 g L1 tryptone,
5 g L1 yeast extract, 10 g L1 NaCl) or LB agar medium (same as
LB medium, with 15 g L1 agar), with appropriate antibiotic
selection (50 mg mL1 apramycin when transformed with
pCRISPomyces2-derived plasmids, 25 mg mL1 chloramphen-
icol to maintain the dam mutation in E. coli ET12567,
25 mg mL1 kanamycin either to maintain helper plasmid
pUB307 or aer insertion of pCAP03-derived plasmids).
S. cerevisiae VL6-48N was used for TAR cloning and grown on
yeast extract peptone (YPD) broth (5 g L1 yeast extract, 10 g L1
peptone, 2% w/v glucose) or YPD agar (same as YPD, withThis journal is © The Royal Society of Chemistry 201815 g L1 agar). Purication of genomic DNA from S. sclerotialus
was performed from a 100 mL liquid culture by phenol-
chloroform extraction.13 The scl gene cluster was captured
using TAR cloning.26 Assembly of plasmid pCAP03-scl was per-
formed following the procedure described by Moore and
colleagues; pCAP03 was a gi from Bradley Moore (Addgene
plasmid # 69862) (see ESI Table S2† for a list of plasmids used in
this study).27 For this purpose String DNA fragments (Thermo
Fisher Scientic) were ordered to include 60-bp hooks homol-
ogous to either side of the scl cluster (ESI Table S2†) and
introduced into pCAP03 via Gibson Assembly (New England
Biolabs). The identity of the captured cluster was conrmed by
PCR amplication and restriction digestion (ESI Fig. S1†).
Insertion of the scl gene cluster in the genome of the heterolo-
gous hosts S. albus and S. coelicolor was accomplished via
intergeneric tri-parental conjugation following the protocol
described by Moore and colleagues.27 CRISPR/Cas9-based
engineering of S. albus strains was performed using plasmids
pCm2-sclM4, pCm2-sclN, pCm2-sclA and pCm2-sclQ1-4. Golden
Gate Assembly was rst performed to insert the specic sgRNAs
into the backbone pCm2 plasmid, then Gibson Assembly was
used to include 800-bp homologous recombination arms, all
following the procedure described by Zhao and colleagues;
pCRISPomyces-2 was a gi from Huimin Zhao (Addgene
plasmid # 61737).15 Clearance of temperature sensitive plas-
mids based on pCm2 was achieved by culturing the mutant
strains on SFM agar medium non-selectively at 39 C.Identication, isolation and structure elucidation of scleric
acid
S. albus strains were cultured for 5 days at 30 C on supple-
mented solid minimal (SM) medium (2 g L1 casaminoacids,
8.68 g L1 TES buﬀer, 15 g L1 agar; aer autoclaving, and just
before use, 10 mL of 50 mM NaH2PO4 + K2HPO4, 5 mL of 1 M
MgSO4, 18 mL of 50% w/v glucose and 1 mL of trace element
solution [0.1 g L1 each of ZnSO4$7H2O, FeSO4$7H2O, MnCl2-
$4H2O, CaCl2$6H2O and NaCl] were added) as described by
Hopwood and colleagues.13 Ethyl acetate was added in equal
volume to the volume of SMmedium used, and acidied to pH 3
by the addition of 37%HCl. The ethyl acetate layer was removed
and evaporated under reduced pressure. The remaining residue
was dissolved in 500 mL of 50 : 50 (v/v) HPLC grade methanol/
water for UHPLC-HRMS analysis. For purication of scleric
acid, 2 L of SM culture medium was used for organic extrac-
tions, and the remaining residue aer evaporation of ethyl
acetate was dissolved in 10 mL 50 : 50 HPLC grade methanol/
water for silica column pre-purication.
UHPLC-HRMS analyses were carried out with 20 mL of
prepared extracts injected through a reverse phase column
(Zorbax Eclipse Plus C18, size 2.1  100 mm, particle size
1.8 mm) connected to a Dionex 3000RS UHPLC coupled to
Bruker Ultra High Resolution (UHR) Q-TOF MS MaXis II mass
spectrometer with an electrospray source. Sodium formate
(10 mM) was used for internal calibration and a m/z scan range
of 50–1500 was used with a gradient elution from 95 : 5 solvent
A/solvent B to 0 : 100 solvent A/solvent B over 10 minutes.Chem. Sci.
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View Article OnlineSolvents A and B were water (0.1% HCOOH) and acetonitrile
(0.1% HCOOH), respectively.
Pre-purication of crude extract containing scleric acid was
performed using ash chromatography. A column was loaded
with C18-reversed phase silica gel, preconditioned with one
volume of methanol, activated with one volume of solvent B
(0.045% v/v triuoroacetic acid in acetonitrile), and equilibrated
with two volumes of solvent A (0.045% v/v triuoroacetic acid in
water). Crude extract was loaded onto the column. Compounds
were then eluted with ve diﬀerent consecutive solvent systems:
two volumes of 20 : 80 solvent B/solvent A, two volumes of
40 : 60 solvent B/solvent A, two volumes of 50 : 50 solvent
B/solvent A, two volumes of 60 : 40 solvent B/solvent A and two
volumes of 80 : 20 solvent B/solvent A. Fractions were collected
throughout the elution steps, evaporated under reduced pres-
sure and dissolved in 500 mL of 50 : 50 (v/v) HPLC grade
methanol/water for UHPLC-HRMS analysis. Fractions contain-
ing scleric acid were combined and used for HPLC purication.
Reverse-phase HPLC was performed using a Zorbax XBD-C18
column (212  150 mm, particle size 5 mm) connected to an
Agilent 1200 HPLC equipped with a binary pump and DAD
detector. Solvent A: 0.1% TFA water, solvent B: 0.1% TFA in
acetonitrile, 5% B to 95%B in 45min. Retention time compound
1: 29.7 min, retention time compound 2 (scleric acid): 34.4 min.
Gradient elution was used (solvent A: water with 0.1% HCOOH,
solvent B: methanol) with a ow rate of 10 mL min1. Fractions
were collected by time or absorbance at 210 nm using an auto-
mated fraction collector. The fractions collected containing
scleric acid were pooled, methanol removed under reduce
pressure and scleric acid was re-extracted from the remaining
water (2  50 mL ethyl acetate). The ethyl acetate was removed
under reduced pressure and the sample re-dissolved in deuter-
ated methanol for NMR analysis.MIC testing
The susceptibility of bacterial strains was investigated in
collaboration with the Warwick Antimicrobial Screening
Facility in a 96-well plate experiment, according to the Clinical &
Laboratory Standards Institute (CLSI) guidelines (M7-A9 2012).
Scleric acid was diluted to a concentration of 7.5 mg mL1 in
25% DMSO in distilled water. To further prevent toxicity eﬀects
from DMSO in MIC testing, 27 mL of the natural product stock
was combined with 173 mL of cation adjusted Muller-Hinton
broth to a nal concentration of 1024 mg mL1 of compound
in 200 mL with 3% DMSO. This was then further doubling
diluted throughout the MIC. Meropenem and cefoxitin were
used as positive controls during MIC testing.Conﬂicts of interest
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